EBGLYSS: cost and payments to doctors
What Medicare Part D paid pharmacies for EBGLYSS, and the payments that named it as the associated drug or biological under the Sunshine Act for program years 2019–2025.
Was your doctor paid by Lilly USA, LLC?
Lilly USA, LLC reported the most payments naming EBGLYSS. Search your clinician to see whether they are among them — and what else they were paid for.
Finding a payment is not a finding of wrongdoing — most reported payments are a meal during a presentation. What matters is the kind, the size, and how it compares with their peers, which is what the profile shows.
- Total reported
- $13M
- Providers
- 15,213
- Transactions
- 76,258
- Average per transaction
- $170
The per-transaction average — $170 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 15,213 providers the average total is $852, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Lilly USA, LLC | $11,968,129 | 92.3% |
| Eli Lilly | $991,499 | 7.6% |
| Eli Lilly Export S.A. Puerto Rico Branch | $3,874 | 0.0% |
Other products from Lilly USA, LLC
The company that reported the most payments naming EBGLYSS also reports against these.